Strategies to Prevent Postdischarge Adverse Events Among Hospitalized Patients with Heart Failure

Heart Failure Clinics

Volumn 9, Issue 3, 2013, Pages 303-320

  Psotka, Mitchell A ^a   Teerlink, John R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute heart failure; Adverse events; Hospitalized heart failure; Mortality; Readmission

Indexed keywords

AMLODIPINE; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; HYDRALAZINE; IVABRADINE; LOOP DIURETIC AGENT; NESIRITIDE; NITRIC ACID DERIVATIVE; NITROPRUSSIDE SODIUM; ROLOFYLLINE; SERELAXIN; TEZOSENTAN; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TROPONIN; VASODILATOR AGENT; WARFARIN;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; EVIDENCE BASED PRACTICE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HOSPITAL READMISSION; HOSPITALIZATION COST; HUMAN; HYPERTENSION; ISCHEMIA; LUNG EDEMA; LUNG EMBOLISM; MEDICARE; MEDICATION THERAPY MANAGEMENT; META ANALYSIS (TOPIC); OUTPATIENT CARE; PATIENT CARE PLANNING; PATIENT EDUCATION; POSITIVE END EXPIRATORY PRESSURE; PREVENTIVE MEDICINE; PULMONARY ARTERY CATHETER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUDDEN CARDIAC DEATH;

HEART FAILURE; HUMANS; INPATIENTS; PATIENT DISCHARGE; PATIENT READMISSION; PRACTICE GUIDELINES AS TOPIC; SURVIVAL RATE; UNITED STATES;

EID: 84879781595     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2013.04.005     Document Type: Review

References (167)

1. Jencks S.F., Williams M.V., Coleman E.A. Rehospitalizations among patients in the Medicare fee-for-service program. NEngl J Med 2009, 360(14):1418-1428.
2. Krumholz H.M. Post-hospital syndrome-an acquired, transient condition of generalized risk. NEngl J Med 2013, 368(2):100-102.
3. Dharmarajan K., Hsieh A.F., Lin Z., et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013, 309(4):355-363.
4. Fang J., Mensah G.A., Croft J.B., et al. Heart failure-related hospitalization in the U.S., 1979 to 2004. JAm Coll Cardiol 2008, 52(6):428-434.
5. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127(1):e6-e245.
6. Harjola V.P., Follath F., Nieminen M.S., et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010, 12(3):239-248.
7. Aranda J.M., Johnson J.W., Conti J.B. Current trends in heart failure readmission rates: analysis of Medicare data. Clin Cardiol 2009, 32(1):47-52.
8. Vashi A.A., Fox J.P., Carr B.G., et al. Use of hospital-based acute care among patients recently discharged from the hospital. JAMA 2013, 309(4):364-371.
9. Bueno H., Ross J.S., Wang Y., et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA 2010, 303(21):2141-2147.
10. Cole R.T., Gheorghiade M., Georgiopoulou V.V., et al. Reassessing the use of vasodilators in heart failure. Expert Rev Cardiovasc Ther 2012, 10(9):1141-1151.
11. Krumholz H.M., Parent E.M., Tu N., et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997, 157(1):99-104.
12. O'Connor C.M., Miller A.B., Blair J.E., et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010, 159(5):841-849.e841.
13. Fonarow G.C., Stough W.G., Abraham W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. JAm Coll Cardiol 2007, 50(8):768-777.
14. Kociol R.D., Hammill B.G., Fonarow G.C., et al. Generalizability and longitudinal outcomes of a national heart failure clinical registry: comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. Am Heart J 2010, 160(5):885-892.
15. Kansagara D., Englander H., Salanitro A., et al. Risk prediction models for hospital readmission: a systematic review. JAMA 2011, 306(15):1688-1698.
16. Solomon S.D., Dobson J., Pocock S., et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007, 116(13):1482-1487.
17. Fonarow G.C., Abraham W.T., Albert N.M., et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007, 297(1):61-70.
18. Nieminen M.S., Brutsaert D., Dickstein K., et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006, 27(22):2725-2736.
19. Blair J.E., Zannad F., Konstam M.A., et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. JAm Coll Cardiol 2008, 52(20):1640-1648.
20. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. NEngl J Med 2006, 355(3):260-269.
21. Ross J.S., Normand S.L., Wang Y., et al. Hospital volume and 30-day mortality for three common medical conditions. N Engl J Med 2010, 362(12):1110-1118.
22. Krumholz H.M., Lin Z., Keenan P.S., et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA 2013, 309(6):587-593.
23. Heidenreich P.A., Sahay A., Kapoor J.R., et al. Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs health care system 2002 to 2006. JAm Coll Cardiol 2010, 56(5):362-368.
24. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. NEngl J Med 1991, 325(5):293-302.
25. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. NEngl J Med 1992, 327(10):685-691.
26. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273(18):1450-1456.
27. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. NEngl J Med 1996, 334(21):1349-1355.
28. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. NEngl J Med 1997, 336(8):525-533.
29. O'Connor C.M., Carson P.E., Miller A.B., et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 1998, 82(7):881-887.
30. Poole-Wilson P.A., Uretsky B.F., Thygesen K., et al. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003, 89(1):42-48.
31. Carson P., Anand I., O'Connor C., et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. JAm Coll Cardiol 2005, 46(12):2329-2334.
32. Remme W.J., Cleland J.G., Erhardt L., et al. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur J Heart Fail 2007, 9(11):1128-1135.
33. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. NEngl J Med 2007, 357(22):2248-2261.
34. Mozaffarian D., Anker S.D., Anand I., et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007, 116(4):392-398.
35. Gissi H.F.I., Tavazzi L., Maggioni A.P., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645):1231-1239.
36. Hamaguchi S., Kinugawa S., Sobirin M.A., et al. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from registry of hospitalized heart failure patients. Circ J 2012, 76(7):1662-1669.
37. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106(17):2194-2199.
38. Konstam M.A., Neaton J.D., Dickstein K., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009, 374(9704):1840-1848.
39. Swedberg K., Komajda M., Bohm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376(9744):875-885.
40. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. NEngl J Med 2011, 364(1):11-21.
41. Dunlay S.M., Redfield M.M., Weston S.A., et al. Hospitalizations after heart failure diagnosis a community perspective. JAm Coll Cardiol 2009, 54(18):1695-1702.
42. Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149(2):209-216.
43. Ghali J.K., Kadakia S., Cooper R., et al. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med 1988, 148(9):2013-2016.
44. Opasich C., Febo O., Riccardi P.G., et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol 1996, 78(3):354-357.
45. Chin M.H., Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health 1997, 87(4):643-648.
46. Michalsen A., Konig G., Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998, 80(5):437-441.
47. Opasich C., Rapezzi C., Lucci D., et al. Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). Am J Cardiol 2001, 88(4):382-387.
48. Klapholz M., Maurer M., Lowe A.M., et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. JAm Coll Cardiol 2004, 43(8):1432-1438.
49. Formiga F., Chivite D., Manito N., et al. Hospitalization due to acute heart failure. Role of the precipitating factors. Int J Cardiol 2007, 120(2):237-241.
50. Fonarow G.C., Abraham W.T., Albert N.M., et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008, 168(8):847-854.
51. Ambardekar A.V., Fonarow G.C., Hernandez A.F., et al. Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-HF). Am Heart J 2009, 158(4):644-652.
52. Logeart D., Isnard R., Resche-Rigon M., et al. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail 2013, 15(4):465-476.
53. Tsuyuki R.T., McKelvie R.S., Arnold J.M., et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001, 161(19):2337-2342.
54. Calvin J.E., Shanbhag S., Avery E., et al. Adherence to evidence-based guidelines for heart failure in physicians and their patients: lessons from the Heart Failure Adherence Retention Trial (HART). Congest Heart Fail 2012, 18(2):73-78.
55. Mockler M., O'Loughlin C., Murphy N., et al. Causes and consequences of nonpersistence with heart failure medication. Am J Cardiol 2009, 103(6):834-838.
56. Riegel B., Lee C.S., Ratcliffe S.J., et al. Predictors of objectively measured medication nonadherence in adults with heart failure. Circ Heart Fail 2012, 5(4):430-436.
57. Wu J.R., Moser D.K., Chung M.L., et al. Predictors of medication adherence using a multidimensional adherence model in patients with heart failure. JCard Fail 2008, 14(7):603-614.
58. Wu J.R., Moser D.K., Chung M.L., et al. Objectively measured, but not self-reported, medication adherence independently predicts event-free survival in patients with heart failure. JCard Fail 2008, 14(3):203-210.
59. Lindenauer P.K., Lagu T., Rothberg M.B., et al. Income inequality and 30 day outcomes after acute myocardial infarction, heart failure, and pneumonia: retrospective cohort study. BMJ 2013, 346:f521.
60. DiMartino L.D., Shea A.M., Hernandez A.F., et al. Use of guideline-recommended therapies for heart failure in the Medicare population. Clin Cardiol 2010, 33(7):400-405.
61. Zhang Y., Wu S.H., Fendrick A.M., et al. Variation in medication adherence in heart failure. JAMA Intern Med 2013, 173(6):468-470.
62. Fonarow G.C., Albert N.M., Curtis A.B., et al. Associations between outpatient heart failure process-of-care measures and mortality. Circulation 2011, 123(15):1601-1610.
63. Felker G.M., Hasselblad V., Hernandez A.F., et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158(3):422-430.
64. Remes J., Miettinen H., Reunanen A., et al. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991, 12(3):315-321.
65. Di Bari M., Pozzi C., Cavallini M.C., et al. The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the ICARe Dicomano Study. JAm Coll Cardiol 2004, 44(8):1601-1608.
66. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33(14):1787-1847.
67. Oghlakian G.O., Sipahi I., Fang J.C. Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?. Mayo Clin Proc 2011, 86(6):531-539.
68. Davis B.R., Kostis J.B., Simpson L.M., et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008, 118(22):2259-2267.
69. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011, 32(6):670-679.
70. Lee D.S., Stitt A., Austin P.C., et al. Prediction of heart failure mortality in emergent care: a cohort study. Ann Intern Med 2012, 156(11):767-775. W-261, W-262.
71. Parrinello G., Di Pasquale P., Torres D., et al. Troponin I release after intravenous treatment with high furosemide doses plus hypertonic saline solution in decompensated heart failure trial (Tra-HSS-Fur). Am Heart J 2012, 164(3):351-357.
72. Metra M., Cotter G., Gheorghiade M., et al. The role of the kidney in heart failure. Eur Heart J 2012, 33(17):2135-2142.
73. O'Connor C.M., Fiuzat M., Lombardi C., et al. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. Circ Heart Fail 2011, 4(6):724-732.
74. Peacock W.F., De Marco T., Fonarow G.C., et al. Cardiac troponin and outcome in acute heart failure. NEngl J Med 2008, 358(20):2117-2126.
75. Metra M., Cotter G., Davison B.A., et al. Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. JAm Coll Cardiol 2013, 61(2):196-206.
76. Teerlink J.R., Cotter G., Davison B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013, 381(9860):29-39.
77. Ashton C.M., Del Junco D.J., Souchek J., et al. The association between the quality of inpatient care and early readmission: a meta-analysis of the evidence. Med Care 1997, 35(10):1044-1059.
78. Ambrosy A.P., Pang P.S., Khan S., et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 2013, 34(11):835-843.
79. Mentz R.J., Hernandez A.F., Stebbins A., et al. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail 2013, 15(4):456-464.
80. Binanay C., Califf R.M., Hasselblad V., et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005, 294(13):1625-1633.
81. Shah M.R., Hasselblad V., Stevenson L.W., et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA 2005, 294(13):1664-1670.
82. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. NEngl J Med 2011, 364(9):797-805.
83. Vizzardi E., Bonadei I., Rovetta R., et al. When should we use nitrates in congestive heart failure?. Cardiovasc Ther 2013, 31(1):27-31.
84. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297(12):1319-1331.
85. Massie B.M., O'Connor C.M., Metra M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. NEngl J Med 2010, 363(15):1419-1428.
86. McMurray J.J., Teerlink J.R., Cotter G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007, 298(17):2009-2019.
87. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. NEngl J Med 2011, 365(1):32-43.
88. Bart B.A., Goldsmith S.R., Lee K.L., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. NEngl J Med 2012, 367(24):2296-2304.
89. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. NEngl J Med 2004, 351(20):2049-2057.
90. Mebazaa A., Parissis J., Porcher R., et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 2011, 37(2):290-301.
91. Mullens W., Abrahams Z., Francis G.S., et al. Sodium nitroprusside for advanced low-output heart failure. JAm Coll Cardiol 2008, 52(3):200-207.
92. Cuffe M.S., Califf R.M., Adams K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287(12):1541-1547.
93. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007, 297(17):1883-1891.
94. Tacon C.L., McCaffrey J., Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 2012, 38(3):359-367.
95. Abraham W.T., Adams K.F., Fonarow G.C., et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). JAm Coll Cardiol 2005, 46(1):57-64.
96. Teerlink J.R., Metra M., Felker G.M., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009, 373:1429-1439.
97. Fonarow G.C., Abraham W.T., Albert N.M., et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007, 153(1). 82.e1-11.
98. Gattis W.A., O'Connor C.M., Gallup D.S., et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. JAm Coll Cardiol 2004, 43(9):1534-1541.
99. Bohm M., Link A., Cai D., et al. Beneficial association of beta-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Crit Care Med 2011, 39(5):940-944.
100. Tracy C.M., Epstein A.E., Darbar D., et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. JAm Coll Cardiol 2013, 61(3):e6-e75.
101. Smith S.C., Benjamin E.J., Bonow R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011, 124(22):2458-2473.
102. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 123(10):e269-e367.
103. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114(10):e385-e484.
104. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
105. Qaseem A., Wilt T.J., Weinberger S.E., et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155(3):179-191.
106. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. NEngl J Med 1986, 314(24):1547-1552.
107. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. NEngl J Med 1987, 316(23):1429-1435.
108. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999, 100(23):2312-2318.
109. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353(9146):9-13.
110. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353(9169):2001-2007.
111. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283(10):1295-1302.
112. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEngl J Med 1999, 341(10):709-717.
113. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. NEngl J Med 2001, 344(22):1651-1658.
114. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. NEngl J Med 2004, 350(21):2140-2150.
115. Phillips C.O., Wright S.M., Kern D.E., et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004, 291(11):1358-1367.
116. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. NEngl J Med 2005, 352(3):225-237.
117. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. NEngl J Med 2005, 352(15):1539-1549.
118. O'Connor C.M., Whellan D.J., Lee K.L., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301(14):1439-1450.
119. Tang A.S., Wells G.A., Talajic M., et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. NEngl J Med 2010, 363(25):2385-2395.
120. Belardinelli R., Georgiou D., Cianci G., et al. 10-year exercise training in chronic heart failure: a randomized controlled trial. JAm Coll Cardiol 2012, 60(16):1521-1528.
121. Takeda A., Taylor S.J., Taylor R.S., et al. Clinical service organisation for heart failure. Cochrane Database Syst Rev 2012, (9). CD002752.
122. Pocock S.J., Ariti C.A., McMurray J.J., et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2012, 34(19):1404-1413.
123. Cohn J.N., Johnson G., Ziesche S., et al. Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. NEngl J Med 1991, 325(5):303-310.
124. Lund L.H., Benson L., Dahlstrom U., et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012, 308(20):2108-2117.
125. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362(9386):777-781.
126. Pitt B., Williams G., Remme W., et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001, 15(1):79-87.
127. McAlister F.A., Ezekowitz J.A., Wiebe N., et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004, 141(5):381-390.
128. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEngl J Med 2002, 346(12):877-883.
129. Homma S., Thompson J.L., Pullicino P.M., et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. NEngl J Med 2012, 366(20):1859-1869.
130. Cleland J.G., Findlay I., Jafri S., et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004, 148(1):157-164.
131. Massie B.M., Collins J.F., Ammon S.E., et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009, 119(12):1616-1624.
132. Rengo G., Pagano G., Squizzato A., et al. Oral anticoagulation therapy in heart failure patients in sinus rhythm: a systematic review and meta-analysis. PLoS One 2013, 8(1):e52952.
133. Teerlink J.R. Ivabradine in heart failure-no paradigm SHIFT. Yet. Lancet 2010, 376(9744):847-849.
134. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. NEngl J Med 1995, 333(2):77-82.
135. Packer M., O'Connor C.M., Ghali J.K., et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. NEngl J Med 1996, 335(15):1107-1114.
136. Mentz R.J., Schmidt P.H., Kwasny M.J., et al. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. JCard Fail 2012, 18(7):515-523.
137. Stefan M.S., Rothberg M.B., Priya A., et al. Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012, 67(11):977-984.
138. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139(2):137-147.
139. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin Pract 2012, 120(4):179-184.
140. Advisory Committee on Immunization Practices Recommended adult immunization schedule: United States, 2013. Ann Intern Med 2013, 158(3):191-199.
141. US Preventive Services Task Force Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 151(10):716-726.
142. Albert N.M., Fonarow G.C., Abraham W.T., et al. Depression and clinical outcomes in heart failure: an OPTIMIZE-HF analysis. Am J Med 2009, 122(4):366-373.
143. Rutledge T., Reis V.A., Linke S.E., et al. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. JAm Coll Cardiol 2006, 48(8):1527-1537.
144. Park J.H., Balmain S., Berry C., et al. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart 2010, 96(7):533-538.
145. Gray A., Goodacre S., Newby D.E., et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. NEngl J Med 2008, 359(2):142-151.
146. Vital F.M., Saconato H., Ladeira M.T., et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema. Cochrane Database Syst Rev 2008, (3). CD005351.
147. Costanzo M.R., Guglin M.E., Saltzberg M.T., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. JAm Coll Cardiol 2007, 49(6):675-683.
148. van der Meer S., Zwerink M., van Brussel M., et al. Effect of outpatient exercise training programmes in patients with chronic heart failure: a systematic review. Eur J Cardiovasc Prev Rehabil 2012, 19(4):795-803.
149. Kinugasa Y., Kato M., Sugihara S., et al. Geriatricnutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 2013, 77(3):705-711.
150. Friedmann J.M., Jensen G.L., Smiciklas-Wright H., et al. Predicting early nonelective hospital readmission in nutritionally compromised older adults. Am J Clin Nutr 1997, 65(6):1714-1720.
151. Kaboli P.J., Go J.T., Hockenberry J., et al. Associations between reduced hospital length of stay and 30-day readmission rate and mortality: 14-year experience in 129 Veterans Affairs hospitals. Ann Intern Med 2012, 157(12):837-845.
152. Chen J., Ross J.S., Carlson M.D., et al. Skilled nursing facility referral and hospital readmission rates after heart failure or myocardial infarction. Am J Med 2012, 125:100.e1-100.e9.
153. Hernandez A.F., Greiner M.A., Fonarow G.C., et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010, 303(17):1716-1722.
154. Viswanathan M., Golin C.E., Jones C.D., et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012, 157(11):785-795.
155. Koelling T.M., Johnson M.L., Cody R.J., et al. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 2005, 111(2):179-185.
156. Juilliere Y., Jourdain P., Suty-Selton C., et al. Therapeutic patient education and all-cause mortality in patients with chronic heart failure: a propensity analysis. Int J Cardiol 2012, [Epub ahead of print].
157. Dinicolantonio J.J., Pasquale P.D., Taylor R.S., et al. Low sodium versus normal sodium diets in systolic heart failure: systematic review and meta-analysis. Heart 2013, [Epub ahead of print].
158. Albert N.M., Nutter B., Forney J., et al. Arandomized controlled pilot study of Outcomes of Strict Allowance of Fluid Therapy in Hyponatremic Heart Failure (SALT-HF). JCard Fail 2013, 19(1):1-9.
159. Myung S.K., Ju W., Cho B., et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013, 346:f10.
160. Giamouzis G., Kalogeropoulos A., Georgiopoulou V., et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. JCard Fail 2011, 17(1):54-75.
161. Chaudhry S.I., Wang Y., Concato J., et al. Patterns of weight change preceding hospitalization for heart failure. Circulation 2007, 116(14):1549-1554.
162. Bui A.L., Fonarow G.C. Home monitoring for heart failure management. JAm Coll Cardiol 2012, 59(2):97-104.
163. Butler J., Subacius H., Vaduganathan M., et al. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) Trial. JAm Coll Cardiol 2013, 61(5):571-579.
164. Blair J.E., Khan S., Konstam M.A., et al. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J 2009, 30(13):1666-1673.
165. Piano M.R., Prasun M.A., Stamos T., et al. Flexible diuretic titration in chronic heart failure: where is the evidence?. JCard Fail 2011, 17(11):944-954.
166. DeBeradinis B., Januzzi J.L. Use of biomarkers to guide outpatient therapy of heart failure. Curr Opin Cardiol 2012, 27(6):661-668.
167. Collins S.P., Pang P.S., Fonarow G.C., et al. Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. JAm Coll Cardiol 2013, 61(2):121-126.